BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AGAH - ECPv5.16.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AGAH
X-ORIGINAL-URL:https://dev.agah.eu
X-WR-CALDESC:Events for AGAH
BEGIN:VTIMEZONE
TZID:Europe/Berlin
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20060326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20061029T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20060219
DTEND;VALUE=DATE:20060222
DTSTAMP:20260929T024653
CREATED:20190314T185621Z
LAST-MODIFIED:20190613T203216Z
UID:3124-1140307200-1140566399@dev.agah.eu
SUMMARY:1st Joint Annual Meeting and 15th AGAH Annual Meeting 2006
DESCRIPTION:Transatlantic Strategies in Early Drug Development\n\n\n\n	Announcement \n\n\n\n\n\n\n\n\n\n\n\n\nFebruary 19-21\, 2006\, Düsseldorf\nThe third joint meeting of the AGAH with the ACCP (American College of Clinical Pharmacology) took place in February 2006 in Düsseldorf. Various international speakers from pharmaceutical industry\, universities and competent authorities present new concepts and discussed actual issues in the fields of human pharmacology. \n\n\n\n\n  \n \n\n\n\n\n\n	Presentations of the Annual Meeting 2006 \n\nJ. Barrett\n1100_Barrett\nApproaching the In Silico Child \n\nB. Bernhard\nB_Bernhard_SV_28.02.06\nCan Healthcare Systems Afford Targeted Medicines? \n\nH. Fuder\nH._Fuder_IV_02.03.06_01\nGaps Between Biomarkers and Surrogate Endpoints: CNS \n\nR. Krishna\nKrishna_SII_28.02.06_01\nApproaches to First-In-Man and Beyond: Early Evidence of Target Engagement with Biomarkers and Innovative Clinical Trial Designs. \n\nJ. Lesko\n1500_Lesko\nTools to Reduce Phase III Trial Failures. \n\nJ. Lütz\nJ._L_tz_SVII_06.03.06_01\nPerspective of the German Medicines Agency (BfArM). BfArM after reorganisation of the structure. \n\nB. Meibohm\nB._Meibohm_SIII_28.02.06\nInterplay between Drug Metabolizing Enzymes \n\nJ. Schentag\nJ._Schentag_SIV_01.03.06_01\nThe Gap Between Biomarkers and Surrogate Endpoints in the Development of Anti-Infectives. \n\nB. Schug\nB._Schug_WS_C_09.03.06\nDrug Interaction Studies \n\nT. Sudhop\nEU-IMPD_02\nWhat is required for first into man? The EU IMPD. \n\nS. Throm\nThrom_SVII_01.03.06_01\nInnovation or Stagnation – Perspective of Pharmaceutical Industry. \n\nG. Wensing\n1200_Wensing\nFrom Preclinical Data to Proof of Concept – Strategies for First to Man Studies. \n\nM. Zühlsdorf\n1630_Z_hlsdorf\nThe gap between biomarkers and surrogate endpoints Oncology
URL:https://dev.agah.eu/event/1st-joint-annual-meeting-and-15th-agah-annual-meeting-2006/
LOCATION:Annual Meeting 2006\, Düsseldorf\, Deutschland
CATEGORIES:Annual Meetings
END:VEVENT
END:VCALENDAR